<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05116215</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-B202105106</org_study_id>
    <nct_id>NCT05116215</nct_id>
  </id_info>
  <brief_title>To Evaluate the Safety of Treating Autoimmune Diseases With Molecular Hydrogen Supplement</brief_title>
  <official_title>To Evaluate the Safety of Treating Autoimmune Diseases With Molecular Hydrogen Supplement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HoHo Biotech</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tri-Service General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>HoHo Biotech</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The supplementation of hydrogen molecules as an aid, adjuvant, may speed up recovering the&#xD;
      course of the disease. The purpose of this study is to determine the safety and possible&#xD;
      efficacy of hydrogen supplements in different formula and dose exposures for a clinical study&#xD;
      in rheumatologic patients. Patients will receive a different dosage of either hydrogen&#xD;
      capsules, hydrogen gas or hydrogen-rich water with their conventional treatment for a month.&#xD;
      Investigators will test for any changes in haematologic, urine analysis and health status&#xD;
      during and following the exposure period.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hydrogen supplement has been shown to have significant removing effects on free radicals.&#xD;
      International clinical trials have shown promise that hydrogen molecules may reduce chronic&#xD;
      inflammatory and then speed up recovering the course of the disease.&#xD;
&#xD;
      The purpose of this study is to determine the safety and possible efficacy of hydrogen&#xD;
      supplements in different formula and dose exposures for a clinical study in rheumatologic&#xD;
      patients.&#xD;
&#xD;
      Study design: 27 rheumatologic patients will be recruited from the Tri-Service General&#xD;
      Hospital for this study. Participants will be screened by doctors for their eligibility and&#xD;
      undergo a series of tests (questionnaires and examinations). Consenting participants will&#xD;
      then be allocated into 3 groups by different dosage forms (Gas, n=9; Water, n=9; Capsules,&#xD;
      n=9). Participants in the gas group will then undergo exposure to 2% H2 in medical air via a&#xD;
      high flow nasal cannula for either 1 (n=3), 2 (n=3) or 4 (n=3) hours every day for one month.&#xD;
      Participants in capsule group will receive 1 (n=3), 3 (n=3) or 6 (n=3) capsules every day for&#xD;
      one month. Participants in the water group will be suggested to drink 1 L hydrogen-rich water&#xD;
      every day for one month. Participants will be examined their regular haematology, urine and&#xD;
      health status before and after the intervention.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 13, 2021</start_date>
  <completion_date type="Anticipated">August 12, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 12, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Blood Routine</measure>
    <time_frame>Change from Baseline Blood Routine at Day 28</time_frame>
    <description>Numerical change in Blood Routine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Urine Routine</measure>
    <time_frame>Change from Baseline Urine Routine at Day 28</time_frame>
    <description>Numerical change in Urine Routine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Health Assessment Questionnaire Disability Index, HAQ-DI</measure>
    <time_frame>Change from Baseline HAQ-DI at Day 28</time_frame>
    <description>Questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease Activity Score, DAS 28</measure>
    <time_frame>Change from Baseline DAS 28 at Day 28</time_frame>
    <description>A score of greater than 5.1 implies active disease, less than 3.2 low disease activity, and less than 2.6 remission.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">27</enrollment>
  <condition>Autoimmune Diseases</condition>
  <arm_group>
    <arm_group_label>Hydrogen inhalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in the gas group will then undergo exposure to 2% H2 in medical air via a high flow nasal cannula for either 1 (n=3), 2 (n=3) or 4 (n=3) hours every day for one month.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hydrogen capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in capsule group will receive either 1 (n=3), 3 (n=3) or 6 (n=3) capsules every day for one month.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hydrogen water</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in the water group will be suggested to drink 1 L hydrogen-rich water every day for one month.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrogen</intervention_name>
    <description>Hydrogen supplement</description>
    <arm_group_label>Hydrogen capsules</arm_group_label>
    <arm_group_label>Hydrogen inhalation</arm_group_label>
    <arm_group_label>Hydrogen water</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 20 to 80&#xD;
&#xD;
          -  Able to compliant with the protocol&#xD;
&#xD;
          -  Able to return to the hospital regularly&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Expected pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kuang-Yih Wang, M.D.</last_name>
    <phone>+886 920757313</phone>
    <email>bbban1024@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tri-Service General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Feng-Cheng Liu, M.D., Ph.D.</last_name>
      <phone>+886 2 87923311</phone>
      <phone_ext>16672</phone_ext>
      <email>lfc10399@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Feng-Cheng Liu, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 8, 2021</study_first_submitted>
  <study_first_submitted_qc>November 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2021</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autoimmune Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

